Comparative Pharmacology
Head-to-head clinical analysis: ENFLURANE versus ULTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENFLURANE versus ULTANE.
ENFLURANE vs ULTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.
Sevoflurane is a volatile general anesthetic that enhances inhibitory neurotransmission via GABA-A and glycine receptors, and inhibits excitatory neurotransmission via NMDA and nicotinic acetylcholine receptors, producing anesthesia, amnesia, and muscle relaxation.
Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.
Inhalation: Induction, 0.5-3% sevoflurane in oxygen or oxygen/nitrous oxide; maintenance, 1.5-3% sevoflurane with or without nitrous oxide.
None Documented
None Documented
Clinical Note
moderateEnflurane + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Enflurane is combined with Fluticasone propionate."
Clinical Note
moderateEnflurane + Methylphenidate
"Enflurane may increase the hypertensive activities of Methylphenidate."
Clinical Note
moderateEnflurane + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Enflurane."
Clinical Note
moderateEnflurane + Clemastine
Terminal elimination half-life is approximately 4-8 hours in adults; context: prolonged with obesity due to high lipid solubility and storage in adipose tissue.
Terminal elimination half-life of inorganic fluoride is approximately 2-5 hours (mean 3.0 h) in adults; context: prolonged with obesity or renal impairment.
Primarily eliminated by pulmonary excretion as unchanged drug (>90%); less than 5% is metabolized via CYP2E1 to fluoride ions and other metabolites, which are renally excreted.
Renal excretion of inorganic fluoride metabolites accounts for >95% of elimination; <5% excreted unchanged in urine.
Category C
Category C
Inhalational Anesthetic
Inhalational Anesthetic
"The risk or severity of adverse effects can be increased when Enflurane is combined with Clemastine."